Press Release

Printer Friendly Version View printer-friendly version
<< Back
POZEN Names Dr. William Kelce as Vice President, Pre-Clinical Development

CHAPEL HILL, N.C., Jun 23, 2005 (BUSINESS WIRE) -- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company focused primarily on products for the treatment of migraine, acute and chronic pain and other pain-related conditions, announced today the appointment of William Kelce Ph.D as Vice President, Pre-Clinical Development. Dr. Kelce will be responsible for all pre-clinical activities including safety pharmacology and toxicology studies supporting all new drug development programs.

Dr. Marshall Reese, POZEN's Executive Vice President, Product Development, said "Dr. Kelce's extensive experience in non-clinical drug development, characterization of drug formulations, pharmacokinetic profiles, optimal dosing schedules, pre-clinical and clinical drug efficacy and safety targets will be a great asset to POZEN in the development of new proprietary drugs."

Dr. Kelce was most recently employed at Pfizer Global Research and Development as Director, Safety Sciences. Prior to joining Pfizer, Dr. Kelce held senior research positions in drug development toxicology for Pharmacia Corporation, G.D. Searle & Company and Monsanto Company. Dr. Kelce has been an adjunct professor at the University of Missouri, School of Medicine, Department of Biochemistry, St. Louis University, School of Medicine, Department of Pharmacological and Physiological Science, and an adjunct associate professor at the School of Medicine, Department of Pediatrics and The Laboratories for Reproductive Biology, University of North Carolina at Chapel Hill.

Dr. Kelce received his A.B. from Washington University, St. Louis, and his M.S. and Ph.D degrees from the University of Missouri-Columbia. He conducted post-doctoral studies in toxicology and endocrinology at The Johns Hopkins University. In addition, Dr. Kelce has received certification as a Fellow in the Academy of Toxicological Sciences.


POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. Since its inception, POZEN has focused its efforts primarily on the development of pharmaceutical products for the treatment of migraine. POZEN is also exploring the development of product candidates in other pain-related therapeutic areas. POZEN has development and commercial alliances with GlaxoSmithKline, Valeant Pharmaceuticals North America, a subsidiary of Valeant Pharmaceuticals International (formerly Xcel Pharmaceuticals, Inc.), and Nycomed Danmark ApS. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website:

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in or unexpected clinical trial results or uncertainties in the timing of clinical trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2005 under "Management's Discussion and Analysis of Financial Condition and Results of Operations." We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.


Bill Hodges, Chief Financial Officer, 919-913-1030
Fran Barsky, Director, Investor Relations, 919-913-1044

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.